scholarly journals El lado más sensible del esófago en relación con el reflujo gastroesofágico. Enseñanzas de ROMA IV

2020 ◽  
Vol 50 (1) ◽  
Author(s):  
José Tawil ◽  
Ronnie Fass
Keyword(s):  
Proton Pump Inhibitor ◽  
Diagnostic Category ◽  
Acid Reflux ◽  
Peripheral Sensitization ◽  
Functional Heartburn ◽  
Proton Pump Inhibitor Treatment ◽  
Esophageal Hypersensitivity ◽  
Inhibitor Treatment ◽  
Rome Iv ◽  
Normal Acid

Rome IV incorporated a new diagnostic category into the functional esophageal disorders group called reflux hypersensitivity. This new name replaced the term hypersensitive esophagus and included patients with normal acid reflux parameters but with symptomatic correlation with reflux events. Functional heartburn, which denoted lack of correlation between symptoms and reflux events in the background of normal pH test, and reflux hypersensitivity, should be excluded in heartburn patients who failed proton pump inhibitor treatment. Reflux hypersensitivity patients demonstrates esophageal hypersensitivity to reflux (any type), and both, reflux hypersensitivity and functional heartburn’s symptoms are driven by central and peripheral sensitization. The correct differentiation between these two esophageal disorders allows a therapeutic approach with greater chance of success. Neuromodulators are considered the mainstay of treatment for these patients even though patients with reflux hypersensitivity demonstrate response to anti-reflux treatment as well.

Sa1107 - Proton Pump Inhibitor Treatment May Reverse Acid Reflux-Induced Gene Changes

2018 ◽  
Vol 154 (6) ◽  
pp. S-242
Author(s):  
Dan Li ◽  
Deepthi Deconda ◽  
Weibiao Cao ◽  
Fadlallah Habr
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Acid Reflux ◽  
Proton Pump Inhibitor Treatment ◽  
Inhibitor Treatment

scholarly journals When does proton pump inhibitor treatment become long term? A scoping review

2021 ◽  
Vol 8 (1) ◽  
pp. e000563
Author(s):  
Peter Fentz Haastrup ◽  
Dorte Ejg Jarbøl ◽  
Wade Thompson ◽  
Jane Møller Hansen ◽  
Jens Søndergaard ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Cochrane Library ◽  
Clinical Context ◽  
Eligibility Criteria ◽  
Proton Pump Inhibitor Treatment ◽  
Common Definition ◽  
Definition Of ◽  
Inhibitor Treatment

ObjectiveProton pump inhibitor (PPI) use has risen substantially, primarily driven by ongoing use over months to years. However, there is no consensus on how to define long-term PPI use. Our objectives were to review and compare definitions of long-term PPI use in existing literature and describe the rationale for each definition. Moreover, we aimed to suggest generally applicable definitions for research and clinical use.DesignThe databases PubMed and Cochrane Library were searched for publications concerning long-term use of PPIs and ClinicalTrials.gov was searched for registered studies. Two reviewers independently screened the titles, abstracts, and full texts in two series and subsequently extracted data.ResultsA total of 742 studies were identified, and 59 met the eligibility criteria. In addition, two ongoing studies were identified. The definition of long-term PPI use varied from >2 weeks to >7 years. The most common definition was ≥1 year or ≥6 months. A total of 12/61 (20%) of the studies rationalised their definition.ConclusionThe definitions of long-term PPI treatment varied substantially between studies and were seldom rationalised.In a clinical context, use of PPI for more than 8 weeks could be a reasonable definition of long-term use in patients with reflux symptoms and more than 4 weeks in patients with dyspepsia or peptic ulcer. For research purposes, 6 months could be a possible definition in pharmacoepidemiological studies, whereas studies of adverse effects may require a tailored definition depending on the necessary exposure time. We recommend to always rationalise the choice of definition.

Sign in / Sign up

Export Citation Format

Share Document